Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression alternations in liraglutide treated rats cardiac muscle

ABSTRACT: Expression alternations in liraglutide treated rats cardiac muscle

PROVIDER: PRJNA397128 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression alternations in liraglutide treated rats cardiac muscle

Project description:Diabetic rats changes gene exprssion in liraglutide treated rats cardiac muscle

2018-03-28 | GSE102194 | GEO

miRNA expression alterations in liraglutide treated rats arota

Project description:liraglutide may distrub miRNA expression in diabetic rats arota

2019-02-11 | GSE102198 | GEO

Expression alternations in liraglutide treated rats cardiac muscle

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-03-30 | GSE102200 | GEO

Rattus norvegicus

Project description:Gene expression alternations in liraglutide treated rats cardiac muscle

| PRJNA397248 | ENA

cardiac proteomics in obese rats

Project description:Cardiac proteome analysis of obese rats treated with mitoQ

2023-06-29 | PXD034955 | JPOST Repository

Oxidative posttranslational modifications of cysteine are associated to high intrinsic aerobic capacity in the skeletal and cardiac muscle

Project description:Oxidative posttranslational modifications (Ox-PTMs) regulate cellular homeostasis in several tissues, including skeletal and cardiac muscles. The putative relationship between Ox-PTMs and intrinsic components of oxidative energy metabolism has not been previously described. We determined the metabolic phenotype and the Ox-PTM profile in the skeletal and cardiac muscles of rats selected for low (LCR) or high (HCR) intrinsic aerobic capacity. The HCR rats have a pronounced increase in mitochondrial content and antioxidant capacity when compared to LCR rats in the skeletal muscle, but only modest changes in the cardiac muscle. Redox proteomics analysis reveals that HCR and LCR rats have different Ox-PTM of cysteine (Cys) residue profile in the skeletal and cardiac muscles. HCR rats have higher number of oxidized Cys residues in the skeletal muscle and conversely display higher number of reduced Cys residues in the cardiac muscle than LCR rats. Most of the proteins with differentially oxidized Cys residues in the skeletal muscle are important regulators of the oxidative metabolism. The most significantly oxidized protein in the skeletal muscle of HCR rats is malate dehydrogenase (MDH1). Interestingly, HCR rats show higher MDH1 activity in the skeletal muscle, but not in the cardiac muscle. Thus, this study uncovers an association between Ox-PTMs and intrinsic aerobic capacity, providing new insights into the role of Ox-PTMs as essential signaling to maintain metabolic homeostasis in different muscle types.

2019-11-12 | PXD009109 | Pride

Gene expression alternations in Shenqi Jiangtang Granule-treated rats kidney

Project description:Gene expression alternations in Shenqi Jiangtang Granule-treated rats kidney

| PRJNA553687 | ENA

Gene expression alternations in Qishen Yiqi Dripping Pill-treated rats kidney

Project description:Gene expression alternations in Qishen Yiqi Dripping Pill-treated rats kidney

| PRJNA553686 | ENA

Gene expression alternations in vildagliptin treated rats arota

Project description:Diabetic rats changes gene exprssion in vildagliptin treated rats arota

2018-04-26 | GSE102196 | GEO

Cardiac Effects of Rosiglitazone in Male Wistar Rats

Project description:Rosiglitazone, a peroxisome proliferator-activated receptor g (PPARg) agonist of the thiazolidinedione class, is a major insulin-sensitizing drug widely used to treat type-2 diabetes. Rosiglitazone causes myocardial hypertrophy in rodents and increases the risk of cardiac events in man. To better characterize its cardiac effects, male Wistar rats were orally administered 0, 10 or 80 mg/kg/day rosiglitazone. Male Wistar rats were orally administered 0, 10 or 80 mg/kg/day rosiglitazone once per day for 14 days. Samples were obtained 6, 24, 168 or 336 hours after the final treatment.

2010-07-29 | E-GEOD-22553 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data